Aditxt, Inc. announced on March 13 the acquisition of Ignite Proteomics, LLC, based in Golden, Colorado.
Under the terms of the transaction documents, Aditxt acquired Ignite in a transaction providing 36,000 shares of Aditxt’s newly designated Series A-2 Convertible Preferred Stock, representing an aggregate stated value of $36 million.
Ignite Proteomics is a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite’s Reverse Phase Protein Array (RPPA) platform is designed to measure protein expression and whether they are functionally active, a distinction that increasingly determines whether a patient would respond to modern targeted therapies. Operating a CLIA‑certified, CAP‑accredited laboratory, Ignite’s clinical RPPA assay quantifies 32 phospho- and total-protein biomarkers from limited biopsy material to support oncology research and clinical decision making. Ignite previously operated as a subsidiary of IMAC Holdings, Inc.
Aditxt is a biotechnology company focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt’s immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system.
Ignite will operate as a subsidiary within Aditxt’s oncology initiatives. Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options.
According to data captured in the LevinPro HC database, this transaction marks the 25th Laboratories, MRI and Dialysis transaction of the year, and the eighth in the laboratories subsector. Throughout all of 2025, there were 138 Laboratories, MRI and Dialysis transactions, 41 of them in the laboratories subsector.
